FindTrial
Sign In

Clinical study to evaluate the role of basti karma (enema therapy) and virechan karma (purgation therapy) in hyperuricemia.

Double arm Clinical trial to evaluate the role of basti karma and virechan karma in hyperuricemia. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/069925
Enrollment
50
Registered
2024-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

None listed

Sponsors

Ayurvedic and Unani Tibbia College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients attending out patient department with Sr. Uric Acid levels greater than 7.0mg/dl will be enrolled in the study.

Exclusion criteria

Exclusion criteria: Patients who are contraindicated for Basti karma will not be included in Group A and for those who are contraindicated for Virechan karma will not be included in Group B. For both groups: Rectal prolapse, Fever, Pregnant and lactating mothers etc. For Group A: Udar rog, intestinal perforation, intestinal obstruction etc. For Group B: Loss of bowel control, atisara(diarrhea) etc Known case of Rheumatoid Arthritis, Psoriatic Arthritis Patients with renal or hepatic impairment (Sr creatinine greater than 1.8mg/dl along with Sr Urea greater than 60 mg/dl, SGOT and SGPT greater than Five times of upper limit Patients having LDL and Triglycerides greater than two times of upper limit Patients with co-morbid conditions such as Hypertension grade 2 greater than equal to 160/100mm of Hg) or more, Diabetes Mellitus (having HbA1c greater than 7.5% with or without hyperglycemicmedications Patients who are on anti tubercular or anti retroviral medication Patients requiring emergency treatment

Design outcomes

Primary

MeasureTime frame
The proportion of patients showing improvement in the level of Sr. Uric acid post Basti karma and Virechan karma. Timepoint: At baseline. 16th day 31st day—

Secondary

MeasureTime frame
Assessment of features of vatarakta in patients of Hyperuricemia.Timepoint: At baseline 16th day 31st day;The proportion of patients showing changes in the inflammatory cytokine IL-6 & CRP post Basti karma & Virechan karma.Timepoint: At baseline 31st day—

Countries

India

Contacts

Public ContactDr Ritika Nagpal

Ayurvedic and Unani Tibbia College and Hospital

nitjin2005@gmail.com9811765501

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026